Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine IV PCA plus pulsed radiofrequency for postherpetic neuralgia (retrospective)
ChiCTR2300069263Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Aug 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine and sufentanil in postherpetic neuralgia (PHN), major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoints: Numerical Rating Scale for pain (NRS), Patient Health Questionnaire-9 (PHQ-9) and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
esketaminesufentanil
03
Conditions
postherpetic neuralgia (PHN)major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2300069263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069263.